Report cover image

Global Clotting Factors ? Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 194 Pages
SKU # APRC20556371

Description

Summary

According to APO Research, the global Clotting Factors Ⅷ market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Clotting Factors Ⅷ is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Clotting Factors Ⅷ is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Clotting Factors Ⅷ market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Clotting Factors Ⅷ is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Clotting Factors Ⅷ market include Taibang Biological, Shanghai Laishi, Lvshizi and Hualan Biological, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Clotting Factors Ⅷ, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Clotting Factors Ⅷ, also provides the sales of main regions and countries. Of the upcoming market potential for Clotting Factors Ⅷ, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Clotting Factors Ⅷ sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Clotting Factors Ⅷ market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Clotting Factors Ⅷ sales, projected growth trends, production technology, application and end-user industry.

Clotting Factors Ⅷ Segment by Company

Taibang Biological
Shanghai Laishi
Lvshizi
Hualan Biological
Clotting Factors Ⅷ Segment by Type

Injection
Freeze-dried Injection
Clotting Factors Ⅷ Segment by Application

Hemophilia A
Bleeding Diseases
Clotting Factors Ⅷ Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Clotting Factors Ⅷ status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Clotting Factors Ⅷ market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Clotting Factors Ⅷ significant trends, drivers, influence factors in global and regions.
6. To analyze Clotting Factors Ⅷ competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Clotting Factors Ⅷ market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Clotting Factors Ⅷ and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Clotting Factors Ⅷ.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Clotting Factors Ⅷ market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Clotting Factors Ⅷ industry.
Chapter 3: Detailed analysis of Clotting Factors Ⅷ manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Clotting Factors Ⅷ in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Clotting Factors Ⅷ in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Clotting Factors Ⅷ Sales Value (2020-2031)
1.2.2 Global Clotting Factors Ⅷ Sales Volume (2020-2031)
1.2.3 Global Clotting Factors Ⅷ Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Clotting Factors Ⅷ Market Dynamics
2.1 Clotting Factors Ⅷ Industry Trends
2.2 Clotting Factors Ⅷ Industry Drivers
2.3 Clotting Factors Ⅷ Industry Opportunities and Challenges
2.4 Clotting Factors Ⅷ Industry Restraints
3 Clotting Factors Ⅷ Market by Company
3.1 Global Clotting Factors Ⅷ Company Revenue Ranking in 2024
3.2 Global Clotting Factors Ⅷ Revenue by Company (2020-2025)
3.3 Global Clotting Factors Ⅷ Sales Volume by Company (2020-2025)
3.4 Global Clotting Factors Ⅷ Average Price by Company (2020-2025)
3.5 Global Clotting Factors Ⅷ Company Ranking (2023-2025)
3.6 Global Clotting Factors Ⅷ Company Manufacturing Base and Headquarters
3.7 Global Clotting Factors Ⅷ Company Product Type and Application
3.8 Global Clotting Factors Ⅷ Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Clotting Factors Ⅷ Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Clotting Factors Ⅷ Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Clotting Factors Ⅷ Market by Type
4.1 Clotting Factors Ⅷ Type Introduction
4.1.1 Injection
4.1.2 Freeze-dried Injection
4.2 Global Clotting Factors Ⅷ Sales Volume by Type
4.2.1 Global Clotting Factors Ⅷ Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Clotting Factors Ⅷ Sales Volume by Type (2020-2031)
4.2.3 Global Clotting Factors Ⅷ Sales Volume Share by Type (2020-2031)
4.3 Global Clotting Factors Ⅷ Sales Value by Type
4.3.1 Global Clotting Factors Ⅷ Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Clotting Factors Ⅷ Sales Value by Type (2020-2031)
4.3.3 Global Clotting Factors Ⅷ Sales Value Share by Type (2020-2031)
5 Clotting Factors Ⅷ Market by Application
5.1 Clotting Factors Ⅷ Application Introduction
5.1.1 Hemophilia A
5.1.2 Bleeding Diseases
5.2 Global Clotting Factors Ⅷ Sales Volume by Application
5.2.1 Global Clotting Factors Ⅷ Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Clotting Factors Ⅷ Sales Volume by Application (2020-2031)
5.2.3 Global Clotting Factors Ⅷ Sales Volume Share by Application (2020-2031)
5.3 Global Clotting Factors Ⅷ Sales Value by Application
5.3.1 Global Clotting Factors Ⅷ Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Clotting Factors Ⅷ Sales Value by Application (2020-2031)
5.3.3 Global Clotting Factors Ⅷ Sales Value Share by Application (2020-2031)
6 Clotting Factors Ⅷ Regional Sales and Value Analysis
6.1 Global Clotting Factors Ⅷ Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Clotting Factors Ⅷ Sales by Region (2020-2031)
6.2.1 Global Clotting Factors Ⅷ Sales by Region: 2020-2025
6.2.2 Global Clotting Factors Ⅷ Sales by Region (2026-2031)
6.3 Global Clotting Factors Ⅷ Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Clotting Factors Ⅷ Sales Value by Region (2020-2031)
6.4.1 Global Clotting Factors Ⅷ Sales Value by Region: 2020-2025
6.4.2 Global Clotting Factors Ⅷ Sales Value by Region (2026-2031)
6.5 Global Clotting Factors Ⅷ Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Clotting Factors Ⅷ Sales Value (2020-2031)
6.6.2 North America Clotting Factors Ⅷ Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Clotting Factors Ⅷ Sales Value (2020-2031)
6.7.2 Europe Clotting Factors Ⅷ Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Clotting Factors Ⅷ Sales Value (2020-2031)
6.8.2 Asia-Pacific Clotting Factors Ⅷ Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Clotting Factors Ⅷ Sales Value (2020-2031)
6.9.2 South America Clotting Factors Ⅷ Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Clotting Factors Ⅷ Sales Value (2020-2031)
6.10.2 Middle East & Africa Clotting Factors Ⅷ Sales Value Share by Country, 2024 VS 2031
7 Clotting Factors Ⅷ Country-level Sales and Value Analysis
7.1 Global Clotting Factors Ⅷ Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Clotting Factors Ⅷ Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Clotting Factors Ⅷ Sales by Country (2020-2031)
7.3.1 Global Clotting Factors Ⅷ Sales by Country (2020-2025)
7.3.2 Global Clotting Factors Ⅷ Sales by Country (2026-2031)
7.4 Global Clotting Factors Ⅷ Sales Value by Country (2020-2031)
7.4.1 Global Clotting Factors Ⅷ Sales Value by Country (2020-2025)
7.4.2 Global Clotting Factors Ⅷ Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.5.2 USA Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.6.2 Canada Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.8.2 Germany Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.9.2 France Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.9.3 France Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.11.2 Italy Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.12.2 Spain Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.13.2 Russia Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.16.2 China Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.16.3 China Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.17.2 Japan Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.19.2 India Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.19.3 India Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.20.2 Australia Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.24.2 Chile Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.26.2 Peru Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.28.2 Israel Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.29.2 UAE Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.31.2 Iran Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Clotting Factors Ⅷ Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Clotting Factors Ⅷ Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Clotting Factors Ⅷ Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Taibang Biological
8.1.1 Taibang Biological Comapny Information
8.1.2 Taibang Biological Business Overview
8.1.3 Taibang Biological Clotting Factors Ⅷ Sales, Value and Gross Margin (2020-2025)
8.1.4 Taibang Biological Clotting Factors Ⅷ Product Portfolio
8.1.5 Taibang Biological Recent Developments
8.2 Shanghai Laishi
8.2.1 Shanghai Laishi Comapny Information
8.2.2 Shanghai Laishi Business Overview
8.2.3 Shanghai Laishi Clotting Factors Ⅷ Sales, Value and Gross Margin (2020-2025)
8.2.4 Shanghai Laishi Clotting Factors Ⅷ Product Portfolio
8.2.5 Shanghai Laishi Recent Developments
8.3 Lvshizi
8.3.1 Lvshizi Comapny Information
8.3.2 Lvshizi Business Overview
8.3.3 Lvshizi Clotting Factors Ⅷ Sales, Value and Gross Margin (2020-2025)
8.3.4 Lvshizi Clotting Factors Ⅷ Product Portfolio
8.3.5 Lvshizi Recent Developments
8.4 Hualan Biological
8.4.1 Hualan Biological Comapny Information
8.4.2 Hualan Biological Business Overview
8.4.3 Hualan Biological Clotting Factors Ⅷ Sales, Value and Gross Margin (2020-2025)
8.4.4 Hualan Biological Clotting Factors Ⅷ Product Portfolio
8.4.5 Hualan Biological Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Clotting Factors Ⅷ Value Chain Analysis
9.1.1 Clotting Factors Ⅷ Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Clotting Factors Ⅷ Sales Mode & Process
9.2 Clotting Factors Ⅷ Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Clotting Factors Ⅷ Distributors
9.2.3 Clotting Factors Ⅷ Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.